Health Care·Biotechnology·$351.5B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.90 | N/A | -3.61% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $1.90 | N/A | -3.61% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concerns over recent performance but remains committed to their strategic goals. They did not provide specific guidance for future quarters.
Management acknowledged the challenges faced in the quarter.
They emphasized a focus on long-term growth despite current setbacks.
AbbVie's earnings report indicates a slight miss on EPS, which contributed to a significant drop in stock price by 6.22%. Investors reacted negatively, likely due to the lack of revenue data and no guidance for future performance. The management's defensive tone suggests they are aware of current challenges but remain focused on long-term objectives.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
HDFC BK LTD ADR
Jan 22, 2019